Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer

被引:66
作者
Sinn, Hans-Peter [1 ]
Schneeweiss, Andreas [2 ]
Keller, Marius [1 ]
Schlombs, Kornelia [6 ]
Laible, Mark [6 ]
Seitz, Julia [2 ]
Lakis, Sotirios [4 ]
Veltrup, Elke [4 ]
Altevogt, Peter [3 ]
Eidt, Sebastian [5 ]
Wirtz, Ralph M. [4 ,5 ]
Marme, Frederik [2 ]
机构
[1] Heidelberg Univ, Inst Pathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany
[2] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Neuenheimer Feld 460, D-69120 Heidelberg, Germany
[3] German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[4] STRATIFYER Mol Pathol GmbH, Werthmannstr 1c, D-50935 Cologne, Germany
[5] St Elizabeth Hosp, Dept Pathol, Werthmannstr 1c, D-50935 Cologne, Germany
[6] BioNTech Diagnost GmbH, D-55131 Mainz, Germany
来源
BMC CANCER | 2017年 / 17卷
关键词
Image analysis; Breast cancer; Ki67; mRNA; RT-qPCR; Prediction; Pathologic complete response; neoadjuvant; Immunohistochemistry (IHC); MammaTyper (R); INTERNATIONAL EXPERT CONSENSUS; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; AUTOMATED ASSESSMENT; MOLECULAR SUBTYPES; PROGNOSTIC VALUE; CORE BIOPSIES; KI67; NEOADJUVANT; EXPRESSION;
D O I
10.1186/s12885-017-3111-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Proliferation may predict response to neoadjuvant therapy of breast cancer and is commonly assessed by manual scoring of slides stained by immunohistochemistry (IHC) for Ki-67 similar to ER and PgR. This method carries significant intra- and inter-observer variability. Automatic scoring of Ki-67 with digital image analysis (qIHC) or assessment of MKI67 gene expression with RT-qPCR may improve diagnostic accuracy. Methods: Ki-67 IHC visual assessment was compared to the IHC nuclear tool (AperioTM) on core biopsies from a randomized neoadjuvant clinical trial. Expression of ESR1, PGR and MKI67 by RT-qPCR was performed on RNA extracted from the same formalin-fixed paraffin-embedded tissue. Concordance between the three methods (vIHC, qIHC and RT-qPCR) was assessed for all 3 markers. The potential of Ki-67 IHC and RT-qPCR to predict pathological complete response (pCR) was evaluated using ROC analysis and non-parametric Mann-Whitney Test. Results: Correlation between methods (qIHC versus RT-qPCR) was high for ER and PgR (spearman's r = 0.82, p < 0.0001 and r = 0.86, p < 0.0001, respectively) resulting in high levels of concordance using predefined cut-offs. When comparing qIHC of ER and PgR with RT-qPCR of ESR1 and PGR the overall agreement was 96.6 and 91.4%, respectively, while overall agreement of visual IHC with RT-qPCR was slightly lower for ER/ESR1 and PR/PGR (91.2 and 92.9%, respectively). In contrast, only a moderate correlation was observed between qIHC and RT-qPCR continuous data for Ki-67/MKI67 (Spearman's r = 0.50, p = 0.0001). Up to now no predictive cut-off for Ki-67 assessment by IHC has been established to predict response to neoadjuvant chemotherapy. Setting the desired sensitivity at 100%, specificity for the prediction of pCR (ypT0ypN0) was significantly higher for mRNA than for protein (68.9% vs. 22.2%). Moreover, the proliferation levels in patients achieving a pCR versus not differed significantly using MKI67 RNA expression (Mann-Whitney p = 0.002), but not with qIHC of Ki-67 (Mann-Whitney p = 0.097) or vIHC of Ki-67 (p = 0.131). Conclusion: Digital image analysis can successfully be implemented for assessing ER, PR and Ki-67. IHC for ER and PR reveals high concordance with RT-qPCR. However, RT- qPCR displays a broader dynamic range and higher sensitivity than IHC. Moreover, correlation between Ki-67 qIHC and RT-qPCR is only moderate and RT-qPCR with MammaTyper (R) outperforms qIHC in predicting pCR. Both methods yield improvements to error-prone manual scoring of Ki-67. However, RT-qPCR was significantly more specific.
引用
收藏
页数:10
相关论文
共 43 条
  • [21] Standardized Ki67 Diagnostics Using Automated Scoring-Clinical Validation in the GeparTrio Breast Cancer Study
    Klauschen, Frederick
    Wienert, Stephan
    Schmitt, Wolfgang D.
    Loibl, Sibylle
    Gerber, Bernd
    Blohmer, Jens-Uwe
    Huober, Jens
    Ruediger, Thomas
    Erbstoesser, Erhard
    Mehta, Keyur
    Lederer, Bianca
    Dietel, Manfred
    Denkert, Carsten
    von Minckwitz, Gunter
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3651 - 3657
  • [22] Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer
    Konsti, Juho
    Lundin, Mikael
    Joensuu, Heikki
    Lehtimaki, Tiina
    Sihto, Harri
    Holli, Kaija
    Turpeenniemi-Hujanen, Taina
    Kataja, Vesa
    Sailas, Liisa
    Isola, Jorma
    Lundin, Johan
    [J]. BMC CLINICAL PATHOLOGY, 2011, 11
  • [23] Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens
    Laible, Mark
    Schlombs, Kornelia
    Kaiser, Katharina
    Veltrup, Elke
    Herlein, Stefanie
    Lakis, Sotiris
    Stoehr, Robert
    Eidt, Sebastian
    Hartmann, Arndt
    Wirtz, Ralph M.
    Sahin, Ugur
    [J]. BMC CANCER, 2016, 16
  • [24] Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
    Luporsi, Elisabeth
    Andre, Fabrice
    Spyratos, Frederique
    Martin, Pierre-Marie
    Jacquemier, Jocelyne
    Penault-Llorca, Frederique
    Tubiana-Mathieu, Nicole
    Sigal-Zafrani, Brigitte
    Arnould, Laurent
    Gompel, Anne
    Egele, Caroline
    Poulet, Bruno
    Clough, Krishna B.
    Crouet, Hubert
    Fourquet, Alain
    Lefranc, Jean-Pierre
    Mathelin, Carole
    Rouyer, Nicolas
    Serin, Daniel
    Spielmann, Marc
    Haugh, Margaret
    Chenard, Marie-Pierre
    Brain, Etienne
    de Cremoux, Patricia
    Bellocq, Jean-Pierre
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 895 - 915
  • [25] Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
    Maisonneuve, Patrick
    Disalvatore, Davide
    Rotmensz, Nicole
    Curigliano, Giuseppe
    Colleoni, Marco
    Dellapasqua, Silvia
    Pruneri, Giancarlo
    Mastropasqua, Mauro G.
    Luini, Alberto
    Bassi, Fabio
    Pagani, Gianmatteo
    Viale, Giuseppe
    Goldhirsch, Aron
    [J]. BREAST CANCER RESEARCH, 2014, 16 (03):
  • [26] Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
    Mauri, D
    Pavlidis, N
    Ioannidis, JPA
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (03): : 188 - 194
  • [27] Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer
    Mohammed, Z. M. A.
    McMillan, D. C.
    Elsberger, B.
    Going, J. J.
    Orange, C.
    Mallon, E.
    Doughty, J. C.
    Edwards, J.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (02) : 383 - 388
  • [28] Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer
    Niikura, Naoki
    Iwamoto, Takayuki
    Masuda, Shinobu
    Kumaki, Nobue
    Tang Xiaoyan
    Shirane, Masatoshi
    Mori, Kazushige
    Tsuda, Banri
    Okamura, Takuho
    Saito, Yuki
    Suzuki, Yasuhiro
    Tokuda, Yutaka
    [J]. CANCER SCIENCE, 2012, 103 (08) : 1508 - 1512
  • [29] Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
    Noske, A.
    Loibl, S.
    Darb-Esfahani, S.
    Roller, M.
    Kronenwett, R.
    Mueller, B. M.
    Steffen, J.
    von Toerne, C.
    Wirtz, R.
    Baumann, I.
    Hoffmann, G.
    Heinrich, G.
    Grasshoff, S. T.
    Ulmer, H. U.
    Denkert, C.
    von Minckwitz, G.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) : 109 - 117
  • [30] Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
    Parker, Joel S.
    Mullins, Michael
    Cheang, Maggie C. U.
    Leung, Samuel
    Voduc, David
    Vickery, Tammi
    Davies, Sherri
    Fauron, Christiane
    He, Xiaping
    Hu, Zhiyuan
    Quackenbush, John F.
    Stijleman, Inge J.
    Palazzo, Juan
    Marron, J. S.
    Nobel, Andrew B.
    Mardis, Elaine
    Nielsen, Torsten O.
    Ellis, Matthew J.
    Perou, Charles M.
    Bernard, Philip S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1160 - 1167